Argenx's Vyvgart fails late-stage Sjögren's disease trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Argenx reported that its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder, marking an unusual setback for the company. The drug was approved for generalized myasthenia gravis and has become a major seller, so the failure removes a potential new indication for its key product.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu